Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
PharmacoEconomics
Erschienen in: PharmacoEconomics 8/2006

01.08.2006 | Original Research Article

Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada

verfasst von: Michele Kohli, Cheryl Attard, Annette Lam, Daniel Huse, John Cook, Chantal Bourgault, Evo Alemao, Donald Yin, Michael Marentette

Erschienen in: PharmacoEconomics | Ausgabe 8/2006

Einloggen, um Zugang zu erhalten

Abstract

Introduction: This analysis compared the cost effectiveness of adding ezetimibe to atorvastatin therapy versus atorvastatin titration or adding cholestyramine (a resin) for patients at high risk of a coronary artery disease (CAD) event who did not reach target cholesterol levels on their current atorvastatin dosage. The primary analysis focused on 65-year-old patients with low-density lipoprotein cholesterol (LDL-C) levels of 3.1 or 3.6 mmol/L with a treatment goal of <2.5 mmol/L, classified as very high risk according to the 2000 Canadian Guidelines for Management and Treatment of Hyperlipidaemia.
Methods: A previously developed Markov model was utilised to capture the cost and clinical consequences of lipid-lowering therapy in primary and secondary prevention of CAD. Comparisons between treatment strategies were made using ICERs (cost per QALY) from a Canadian Ministry of Health perspective. The effects of lipid-lowering therapies were based on clinical trial data. The risks of CAD events were estimated using Framingham Heart Study risk equations. Treatment costs and the costs of acute and long-term care for CAD events were included in the analysis. Costs ($Can, 2002 values) and outcomes were discounted at 5% per annum.
Results: Ezetimibe added to atorvastatin therapy compared with treatment with the most common fixed atorvastatin daily dosage (10mg) or with common atorvastatin titration strategies (up to 20mg daily; up to 40mg daily) resulted in cost per QALY estimates ranging from $Can25 344 to $Can44 332. The addition of ezetimibe to atorvastatin therapy was less costly and more effective than the addition of cholestyramine (dominant).
Conclusion: Our analysis suggests that adding ezetimibe to atorvastatin for patients not achieving treatment goals with their current atorvastatin dose produces greater clinical benefits than treatment with a fixed-dose atorvastatin or atorvastatin titration at an increased overall cost. The cost-effectiveness ratios provide strong evidence for the adoption of ezetimibe within the Canadian healthcare system.
Fußnoten
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literatur
1.
Heart and Stroke Foundation of Canada. The growing burden of heart disease and stroke in Canada. Ottawa (ON): Heart and Stroke Foundation of Canada, 2003
2.
Health Canada. Economic burden of illness in Canada, 1998. Ottawa (ON): Health Canada, 2002
3.
Start with your heart [online]. Available from URL: http://​startwithyourhea​rt.​com/​Default.​htm?​.​page=​http%3A//startw ithyourheart.com/glossary.htm [Accessed 2004 May 1]
4.
Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97: 946–52PubMedCrossRef
5.
Bang LM, Goa KL. Pravastatin: a review of its use in elderly patients. Drugs Aging 2003; 20: 1061–82PubMedCrossRef
6.
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–22PubMedCrossRef
7.
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9
8.
Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–9PubMedCrossRef
9.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57CrossRef
10.
Genest J, Frohlich J, Fodor G, et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003; 169: 921–4PubMed
11.
Kastelein J, Van Dam M. A new role for combination therapy in lipid management. Br J Cardiol 2001; 8 (11): 639–53
12.
Fodor JG, Frohlich JJ, Genest Jr JJ, et al. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ 2000; 162: 1441–7PubMed
13.
Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol 2000; 86 (12A): 35L–40LPubMedCrossRef
14.
Chong PH, Bachenheimer BS. Current, new and future treat-ments in dyslipidaemia and atherosclerosis. Drugs 2000; 60 (1): 55–93PubMedCrossRef
15.
Turley SD. State of the art in cholesterol management: targeting multiple pathways. Am J Manag Care 2002; 8 (2 Suppl.): 29S–32S
16.
Repchinshky C, Welbanks L, Bisson R, editors. CPS — compendium of pharmaceuticals and specialties. Ottawa (ON): Canadian Pharmaceutical Association, 2002
17.
IMS Health Canada. Canadian Compuscript Audit, TRx moving annual total, Kirkland (QC). 2003 Dec
18.
Gangé C, Gaudet D, Bruckert E; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105: 2469–75CrossRef
19.
Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125–34PubMedCrossRef
20.
Bureau of Pharmaceutical Assessment. PROTOCOL P00692: a phase III double-blind efficacy and safety study of ezetimibe (SCH 58235) 10mg in addition to atorvastatin compared to placebo in subjects with primary hypercholesterolemia. 2003. 10-18-0001 (Data on file)
21.
Ballantyne C, Houri J, Notarbartolo A, et al., for the Ezetimibe Study Group. Effect of ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107 (19): 2409–15PubMedCrossRef
22.
Melani L, Mills R, Hassman D, et al., for the Ezetimibe Study Group. Ezetimibe co-administered with pravastatin in 538 patients with primary hypercholesterolemia [abstract]. J Am Coll Cardiol 2002; 39: 139B
23.
Lipka L, Kerzner B, Corbelli J, et al. Results of ezetimibe co-administered with lovastatin in 548 patients with primary hypercholesterolemia [abstract]. J Am Coll Cardiol 2003; 39: 430B
24.
Knopp RH, Dujovne CA, Le Beaut A, et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolemia: a pooled analysis from two controlled phase III clinical studies. Ezetimbe Study Group. Int J Clin Pract 2003 Jun; 57 (5): 363–8PubMed
25.
Gagné C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002 Nov 15; 90 (10): 1084–91PubMedCrossRef
26.
Ballantyne CM, Lipka LJ, Sager PT, et al. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract 2004 Jul; 58 (7): 653–8PubMedCrossRef
27.
Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005 May; 80 (5): 587–95PubMedCrossRef
28.
Cook JR, Yin D, Alemao E, et al. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. Pharmacoeconomics 2004; 22 Suppl. 3: 37–48PubMed
29.
Cook JR, Yin D, Alemao E, et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal. Application to Germany, Spain and Norway. Pharmacoeconomics 2004; 22 Suppl. 3: 49–61PubMed
30.
Glick H, Heyse JF, Thompson D, et al. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. Int J Technol Assess Health Care 1992; 8 (4): 719–34PubMedCrossRef
31.
Weinstein MC, Coxson PG, Williams LW, et al. Forecasting coronary heart disease incidence, mortality, and cost: the coronary heart disease policy model. Am J Public Health 1987; 77: 1417–26PubMedCrossRef
32.
Oster G, Epstein AM. Primary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol. Am J Public Health 1986; 76 (6): 647–56PubMedCrossRef
33.
Oster G, Epstein AM. Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease: the case of cholestyramine. JAMA 1987; 258 (17): 2381–7PubMedCrossRef
34.
Goldman L, Weinstein MC, Goldman PA, et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265 (9): 1145–51PubMedCrossRef
35.
Hamilton VH, Racicot FE, Zowall H, et al. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: estimating the benefits of increasing HDL-C. JAMA 1995; 273 (13): 1032–8PubMedCrossRef
36.
Huse DM, Russell MW, Miller JD, et al. Cost-effectiveness of statins. Am J Cardiol 1998; 82 (11): 1357–63PubMedCrossRef
37.
Russell MW, Huse DM, Miller JD, et al. Cost effectiveness of HMG-CoA reductase inhibition in Canada. Can J Clin Pharmacol 2001; 8 (1): 9–16PubMed
38.
D’Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from The Framingham Study. Am Heart J 2000; 139: 272–81PubMedCrossRef
39.
Kenemans P. Climacteric and postmenopause: definitions, terms and concept [online]. 2002 Oct 17. Available from URL: http: //www.womanlab.com/english/professionals/menopausalIssues1.htm [Accessed 2003 Mar 13]
40.
Anderson K, Odell P, Wilson P, et al. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293–8PubMedCrossRef
41.
Elveback LR, Connolly DC, Kurland LT. Coronary heart dis-ease in residents of Rochester, Minnesota: II. Mortality, incidence, and survivorship, 1950–1975. Mayo Clin Proc 1981; 56 (11): 665–72PubMed
42.
Eisenberg MS, Hallstrom A, Bergner L. Long-term survival after out-of-hospital cardiac arrest. N Engl J Med 1982; 306 (22): 1340–3PubMedCrossRef
43.
Gillum RF, Folsom A, Luepker RV, et al. Sudden death and acute myocardial infarction in a metropolitan area, 1970–1980. The Minnesota Heart Survey. N Engl J Med 1983; 309 (22): 1353–8PubMedCrossRef
44.
Goldman L, Cook F, Hashimotso B, et al. Evidence that hospital care for acute myocardial infarction has not contributed to the decline in coronary mortality between 1973–1974 and 1978–1979. Circulation 1982; 65 (5): 936–42PubMedCrossRef
45.
McGovern PG, Jacobs Jr DR, Shahar E, et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey. Circulation 2001; 104 (1): 19–24PubMedCrossRef
46.
Statistics Canada. Annual demographic statistics 2000 (catalogue 91-213). Ottawa (ON): Minister of Industry, 2001
47.
The North American Menopause Society. Menopause Core Curriculum Study Guide [introduction]. 2002: 9–14
48.
Connelly PW, MacLean DR, Horlick L, et al. Plasma lipids and lipoproteins and the prevalence of risk for coronary heart disease in Canadian adults. Canadian Heart Health Surveys Research Group. CMAJ 1992; 146: 1977–87PubMed
49.
Stachenko SJ, Reeder BA, Lindsay E, et al. Smoking prevalence and associated risk factors in Canadian adults. Canadian Heart Health Surveys Research Group. CMAJ 1992; 146: 1989–96PubMed
50.
Joffres MR, Hamet P, Rabkin SW, et al. Prevalence, control and awareness of high blood pressure among Canadian adults. Canadian Heart Health Surveys Research Group. CMAJ 1992; 146: 1997–2005PubMed
51.
Reeder BA, Liu L, Horlick L. Sociodemographic variation in the prevalence of cardiovascular disease. Can J Cardiol 1996; 12 (3): 271–7PubMed
52.
Hux JE, Tang M. Patterns of prevalence and incidence of diabetes. Diabetes in Ontario practice atlas. Toronto (ON): Institute for Clinical Evaluative Sciences, 2002
53.
Grover SA, Paquet S, Levinton C, et al. Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. Arch Intern Med 1998; 158: 655–62PubMedCrossRef
54.
Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004; 148 (3): 447–55PubMedCrossRef
55.
Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001; 4 (5): 348–61PubMedCrossRef
56.
Hunink MG, Goldman L, Tosteson AN, et al. The recent decline in mortality from coronary heart disease, 1980–1990: the effect of secular trends in risk factors and treatment. JAMA 1997; 277: 535–42CrossRef
57.
Heart and Stroke Foundation of Canada. The changing face of heart disease and stroke in Canada. Ottawa (ON): Heart and Stroke Foundation of Canada, 1999: 1–107
58.
53. Metabolism-Atherogenesis Branch, National Heart, Lung, and Blood Institute, et al. The lipid research clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–64CrossRef
59.
Sprecher DL, Abrams J, Allen JW, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994; 120: 537–43PubMed
60.
Bureau of Pharmaceutical Assessment. PROTOCOL P00693: a phase III double-blind efficacy and safety study of SCH 58235 (10mg) in addition to atorvastatin in subjects with coronary heart disease or multiple cardiovascular risk factors and with primary hypercholesterolemia not controlled by a starting dose (10mg) of atorvastatin 2003. 1-31-0002. (Data on file)
61.
Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med 1993; 153: 1321–9CrossRef
62.
Bureau of Pharmaceutical Assessment. PROTOCOLS P02173 & P02246: a multicenter, double-blind, randomized, placebo-controlled study to evaluate the lipid altering efficacy, safety, and tolerability of SCH 58235 when added to ongoing therapy with an HMG-CoA reductase inhibitor (statin) in patients with primary hypercholesterolemia, known coronary heart disease, or multiple cardiovascular risk factors [base study]. 2003. 11-9-0001. (Data on file)
63.
Ontario Ministry of Health. Ontario drug benefit formulary: comparative drug index. 37th ed. Toronto (ON): Ontario Ministry of Health, 2001
64.
Ontario Ministry of Health. Ontario schedule of benefits for physician services under the Health Insurance Act. Toronto (ON): Ontario Ministry of Health, 2001
65.
Ontario Ministry of Health. Ontario schedule of benefits for laboratory services. Toronto (ON): Ontario Ministry of Health, 1999
66.
Grover SA, Coupal L, Zowall H, et al. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001; 24: 45–50PubMedCrossRef
67.
O’Brien JA, Caro I, Getsios D, et al. Diabetes in Canada: direct medical costs of major macrovascular complications. Value Health 2001; 4: 258–65PubMedCrossRef
68.
Statistics Canada. The consumer price index. Ottawa (ON): Statistics Canada, 2003
69.
Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile: a statement for health professionals. Circulation 1991; 83: 356–62PubMedCrossRef
70.
Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13: 89–102PubMedCrossRef
71.
Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. Ottawa (ON): CCOHTA Publications, 1997
72.
Grover SA, Ho V, Lavoie F, et al. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? 2003; 163 (3): 333–9
73.
Pasternak RC, Smith Jr SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567–72PubMedCrossRef
74.
75.
Ballantyne CM, Corsini A, Davidson MIL et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163: 553–64PubMedCrossRef
76.
Perreault S, Hamilton VH, Lavoie F, et al. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc Drugs Ther 1997; 10: 787–94PubMedCrossRef
77.
Riviere M, Wang S, Leclerc C, et al. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. CMAJ 1997; 156: 991–7PubMed
78.
Perreault S, Hamilton VH, Lavoie F, et al. Treating hyperlipidemia for the primary prevention of coronary disease: are higher dosages of lovastatin cost-effective? Arch Intern Med 1998; 158: 375–81PubMedCrossRef
79.
Perreault S, Levinton C, Le Lorier J. Efficacy and cost of HMG-CoA reductase inhibitors in the treatment of patients with primary hyperlipidemia. Can J Clin Pharmacol 2000; 7: 144–54PubMed
80.
Ganz DA, Kuntz KM, Jacobson GA, et al. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme: a reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000; 132: 780–7PubMed
81.
Jonsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart 1996; 17: 1001–7CrossRef
82.
Muls E, Van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis 1998; 137 Suppl.: Sl11–6
83.
Pickin DM, McCabe CJ, Ramsay LE, et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999; 82 (3): 325–32PubMed
84.
Troche CJ, Tacke J, Hinzpeter B, et al. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur Heart J 1998; 19 Suppl. C: C59–65PubMed
85.
Tsevat J, Kuntz KM, Orav EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart 2001; 141: 727–34CrossRef
Metadaten
Titel
Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada
verfasst von
Michele Kohli
Cheryl Attard
Annette Lam
Daniel Huse
John Cook
Chantal Bourgault
Evo Alemao
Donald Yin
Michael Marentette
Publikationsdatum
01.08.2006
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 8/2006
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200624080-00007

Weitere Artikel der Ausgabe 8/2006

PharmacoEconomics 8/2006 Zur Ausgabe

Correspondence

National-Level Purchasing of Expensive Drugs is Increasing Pressure on the Hospital Drug Budget

Original Research Article

A Multi-Country Health Economic Evaluation of Highly Concentrated N-3 Polyunsaturated Fatty Acids in Secondary Prevention after Myocardial Infarction

Original Research Article

Costs of Inflammatory Bowel Disease in Germany

Review Article

A Comparative Review of Health-Related Quality-of-Life Measures for Use in HIV/AIDS Clinical Trials

Review Article

Prostaglandin Analogues for the Treatment of Glaucoma and Ocular Hypertension

Original Research Article

Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease